{"id":4165,"date":"2024-04-26T11:18:49","date_gmt":"2024-04-26T03:18:49","guid":{"rendered":"https:\/\/flcube.com\/?p=4165"},"modified":"2025-02-17T14:02:01","modified_gmt":"2025-02-17T06:02:01","slug":"yantai-lannacheng-biotech-secures-rmb-300-million-in-series-b-financing-round","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=4165","title":{"rendered":"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round"},"content":{"rendered":"\n

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675<\/a>) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management and other investors. Previously valued at RMB 1.95 billion (USD 270 million), Lannacheng now has a registered capital of RMB 84.58 million, indicating that an initial public offering (IPO) may be in the near future.<\/p>\n\n\n\n

Established in 2021, Lannacheng Bio is dedicated to the research and development of oncology-focused nuclear medicines. The company’s pipeline includes treatments for a range of cancers such as prostate cancer, solid tumors, gliomas, and neuroendocrine tumors. Their therapeutic approach encompasses targeted small molecules, peptides, and antibodies.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,158,20,3692,937],"class_list":["post-4165","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-dongcheng-pharmaceutical","tag-finance","tag-lannacheng-biotechnology","tag-she-002675"],"yoast_head":"\nYantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management and other investors. Previously valued at RMB 1.95 billion (USD 270 million), Lannacheng now has a registered capital of RMB 84.58 million, indicating that an initial public offering (IPO) may be in the near future.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=4165\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=4165\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-26T03:18:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-17T06:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4165#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4165\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round\",\"datePublished\":\"2024-04-26T03:18:49+00:00\",\"dateModified\":\"2025-02-17T06:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4165\"},\"wordCount\":139,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Dongcheng Pharmaceutical\",\"Finance\",\"Lannacheng Biotechnology\",\"SHE: 002675\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4165#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4165\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=4165\",\"name\":\"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-26T03:18:49+00:00\",\"dateModified\":\"2025-02-17T06:02:01+00:00\",\"description\":\"Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management and other investors. Previously valued at RMB 1.95 billion (USD 270 million), Lannacheng now has a registered capital of RMB 84.58 million, indicating that an initial public offering (IPO) may be in the near future.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4165#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4165\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4165#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round - Insight, China's Pharmaceutical Industry","description":"Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management and other investors. Previously valued at RMB 1.95 billion (USD 270 million), Lannacheng now has a registered capital of RMB 84.58 million, indicating that an initial public offering (IPO) may be in the near future.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=4165","og_locale":"en_US","og_type":"article","og_title":"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=4165","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-26T03:18:49+00:00","article_modified_time":"2025-02-17T06:02:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=4165#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=4165"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round","datePublished":"2024-04-26T03:18:49+00:00","dateModified":"2025-02-17T06:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=4165"},"wordCount":139,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Dongcheng Pharmaceutical","Finance","Lannacheng Biotechnology","SHE: 002675"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=4165#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=4165","url":"https:\/\/flcube.com\/?p=4165","name":"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-26T03:18:49+00:00","dateModified":"2025-02-17T06:02:01+00:00","description":"Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management and other investors. Previously valued at RMB 1.95 billion (USD 270 million), Lannacheng now has a registered capital of RMB 84.58 million, indicating that an initial public offering (IPO) may be in the near future.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=4165#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=4165"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=4165#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4165"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4165\/revisions"}],"predecessor-version":[{"id":9152,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4165\/revisions\/9152"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}